INVESTORS

Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.

 

About Us

Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Sep 20, 2022

TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke Market $2.7 Billion by 2029 NEW YORK, Sept. 20, 2022 /PRNewswire/ --...

Sep 6, 2022

Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc....

Aug 12, 2022

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons
  • SEC Filings
    View annual filings, quarterly filings and more
  • FAQ's
    Check out our frequently asked questions for more information
  • Events
    Upcoming and past investor related events and announcements
Investor Presentation

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Download

Subscribe
Keep up to date on Hoth Therapeutics News. Simply fill out your email below and you will be added to our email alerts.
* Required Fields
Our Pipeline

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Investor Contact

LR Advisors LLC

Email: investorrelations@hoththerapeutics.com

Phone: (678) 570-6791